62 results about "Pharmacologic Agent" patented technology

Apparatus and methods for performing retrograde perfusion, especially during cardiopulmonary bypass operations, including dedicated pediatric scaled apparatus for retrograde perfusion of an adult human organ, organ system, or limb, especially the brain, employing small scale oxygenators and heat exchangers such as are designed for pediatric surgery; also including methods and apparatus for retrograde cerebral perfusion, using nonselective infravalvular cannulation of the superior vena cava, estimating the efficacy of cerebral perfusion by monitoring fluid flow across a valve of an internal jugular vein, modification of inflow pressure and administration of pharmacologic agents, and increasing fluid flow into a brain by occlusion of an inferior vena cava distal to its junction with an azygos vein.

An implantable refillable device to deliver pharmacologic agents through a sclera to an internal portion of an eye is shown. The device comprises a hollow reservoir and a delivery tube. The delivery tube has a proximal end and a distal end. The proximal end communicates with the hollow reservoir and the distal end terminates in a dispensing outlet. The delivery tube is configured in a selected shape to extend from the hollow reservoir anterior in an eye to a posterior segment posterior in an eye adjoining a sclera. The second end is configured to position the dispensing outlet in contact with or contiguous the sclera and is located posteriorly in an eye and proximate to an internal portion of an eye to be treated with a pharmacologic agent. An implantable device to deliver pharmacologic agents through an outer surface tissue of an organ is also shown.

Therapeutic compositions of microspheres for application to wounds and/or lesions for accelerating wound healing and muscle regeneration. The microspheres are made up of non-biodegradable material having a substantial surface charge. The therapeutic composition further includes a pharmaceutically acceptable carrier in which the microspheres are insoluble and a container for holding the composition. The therapeutic composition further contains pharmacologic agents or biologics that accelerate the wound healing process.

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.

A method increases the depth of focus of an eye having a line of sight. A pharmacologic agent is applied to the eye to cause a reduction in the size of the pupil of the eye. The pupil is aligned with a visible feature of a mask comprising a pin-hole aperture. The pin-hole aperture is centered on a mask axis. The alignment causes the mask axis to be substantially aligned with the line of sight of the eye. The mask is applied to the eye of the patient while maintaining the alignment of the visible feature of the mask and the pupil.

A method for extracting and detecting analytes that are metabolically associated with biological samples, as well as, for distinguishing between those which are environmentally associated and those which are metabolically incorporated is disclosed.

The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

A method to serially determine changes in perfusion to tissues is provided. This method involves injecting contrast material into a catheter that is positioned in the blood supply proximal to the targeted tissue of interest, acquiring a time series of images that depicts the uptake of this contrast material within the tissue, deriving semi-quantitative or quantitative perfusion metrics based upon the time series of perfusion images, altering perfusion to the targeted tissue by means of injecting pharmacologic agents or embolic agents into the blood vessels supplying the targeted tissue, repeating the acquisition of perfusion images to serially monitor changes in tissue perfusion after each alteration, and calculating changes in perfusion metrics after each series of perfusion images. This method is used to monitor changes in perfusion to various tissues, including a diverse array of tumors. The perfusion imaging method can be acquired using magnetic resonance, x-ray computed tomography, or radionuclide imaging. The perfusion metric is serially measured during an embolization procedure as a means of measuring changes in tissue perfusion or to target an endpoint based upon a specific alteration in the calculated perfusion metric.

An apparatus for comminuting biological specimens includes a receiving component provided with a drive source, a sample retainer configured for retaining at least one biological specimen and for engagement in the receiving component, and a single use comminution mechanism in operational relationship with the sample retainer. The drive source is configured for driving the comminution mechanism. A collector is associated with the receiving component for receiving comminuted product generated by the comminution mechanism. A method for comminuting biological specimens is provided so that, upon comminution, the specimen is readily subject to rapid extraction and detection of drugs and their metabolites, compounds, chemicals, pesticides, steroids, growth enhancers, contaminants or other pharmacologic agents which may reside in the specimen.

The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy.

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments.

A system and method for personalized dosing of a pharmacologic agent include: executing, using a processing device, a plurality of dosing regimen program modules to determine a respective plurality of dose sets in response to receiving, from an input device, a target response value for a patient; and executing, using the processing device, a dosing selection algorithm module, following executing the plurality of dosing regimen program modules and in response to receiving from the input device a response profile and a monitoring frequency of the patient, to determine a recommended dose set computed as a combination of the plurality of dose sets weighted by degrees of matching computed using fuzzy sets and the response profile.

The invention relates to a traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases, mainly containing one or more of Salvia miltiorrhiza, folium ginkgo, panax notoginseng, kudzuvine root Pueraria lobata, rhizoma ligustici wallichii, hawthorn and lotus leaf. The preparation method comprises the steps of selecting one or more of the Salvia miltiorrhiza, the folium ginkgo, the panax notoginseng, the kudzuvine root Pueraria lobata, the rhizoma ligustici wallichii and the hawthorn and lotus leaf, decocting, extracting active ingredients and concentrating the extracting solution to a certain concentration to obtain the Chinese traditional medicine preparation. In addition, the concentrated solution can be further made into capsules, tablets, granules, oral liquid, pills, pulvis, injection and sustained and controlled release preparations. Toxicologic and pharmacologic agent experiments show that the invention has no toxic side effect, is safe to use, has the functions of promoting blood circulation, remove blood stasis, reducing fat, freeing channels and eliminating phlegm and is suitable for phlegm stasis internal-block type cardiovascular and cerebrovascular diseases.

Treatment of malignant tumors or other lesions by localized transfer of radio frequency electromagnetic energy into a portion of the body may be achieved by means of spatially localized magnetic resonance (MR). A magnetic field with appropriate spatial distribution and radio frequency tuned to the resonant frequency unique to the tumor treatment volume will cause selective therapeutic energy deposition or heating within the tumor (hyperthermia). The desired magnetic field distribution for the MR treatment volume may be achieved by means of a main static magnetic field with a superimposed magnetic field to define the treatment volume size and shape, positioned by a gradient magnetic field. Treatment may be enhanced by MR contrast agents (such as gadolinium) and pharmacologic agents. The therapy may be achieved by simultaneous resonance throughout an entire selected therapy volume, or successively point by point, or by superimposition of small volumes, including by successively excited points, lines or planes as practiced in prior art magnetic resonance imaging systems, facilitating simultaneous imaging and therapy. In a preferred embodiment, the invention is incorporated in a magnetic resonance imaging (MRI) scanner wherein the imager modified by the addition of a localizing magnet is used visually or by automated or semi-automated computer image processing to define and localize the treatment volume and the main magnetic field and positioning gradient fields are created by the same magnets used for imaging and the radio frequency apparatus used for Magnetic Resonance Therapy uses the same electronics and probe coil used for MRI.

The present invention relates to a method of treatment of a disease comprising the step of administering to an animal a paradoxical pharmacologic agent, wherein the agent restores compensatory mechanisms or activates redundant mechanisms. More particularly, the invention relates to methods of treatment for hypertension.

Methods and systems for evaluating biological dataset profiles relating to asthma and other atopic conditions are provided, where datasets comprising information for multiple cellular parameters are compared and identified, and used in the evaluation of candidate pharmacologic agents for suitability as therapeutic agents.

The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

Screening methods are provided for identifying pharmacologic inhibitors of HCV amphipathic helix (AH) function, which inhibitors are useful in the prevention and treatment of HCV infection. Also provided are compounds useful in the inhibition of viral replication. The methods of the invention are based on the unexpected discovery that the presence of an AH, e.g. an AH of an HCV polypeptide, causes an increase in the apparent diameter of the vesicles. The methods of the invention provide for addition of AH peptides to lipid vesicles, for example in a high-throughput format; which addition may be performed in the absence or presence of a candidate pharmacologic agent. The change in apparent vesicle size is measured, and compared to control samples. An increase in vesicle size or aggregation is indicative of AH function being present; and a lack of increase is indicative that the AH function is absent or has been inhibited by a test agent.

A method of pharmaceutically managing snoring and impaired breathing is provided. This invention relates to treating snoring, sleep apnea, and other forms of sleep-disordered breathing in those with or without symptoms of or the diagnosis of gastro-intestinal reflux disease (GERD). It comprises administration of a therapeutically effective dose of Prevacid (Lansoprazole) or any other medication that can be used to treat symptoms of hyper-acidity or gastrointestinal reflux disease (GERD). The therapeutic medication may be used alone or in combination with other pharmacologic agents or mechanical modalities including but not limited to decongestants, antihistamines or mechanical nasal toilet. It also is of benefit in improving breathing disorders that are present while awake.